Prognostic Importance Of Measurable Residual Disease (Mrd) Kinetics And Progression-Free Survival (Pfs) Benefit In Mrd Plus Patients (Pts) With Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results From The Multicenter, Double-Blind, Phase 3 Tourmaline-Mm4 Trial In Non-Transplant Newly Diagnosed Multiple Myeloma (Ndmm) Pts